Table III.
Immunohistochemical analysis of protein expression of five candidate proteins in 30 primary breast cancer biopsies stratified according to recurrence and receptor status within a 10-year period
| HLA-DRα/β | CD74 | NDRG1 | Integrin β1 | Ecto-5′-NT | |
|---|---|---|---|---|---|
| ER+/PR+ in cancer cells of primary tumor (n = 12) | |||||
| Relapse within a 10-year period | 14% (1/7a) | 29% (2/7) | 43% (3/7) | 57% (4/7) | 71% (5/7) |
| No relapse within a 10-year period | 0% (0/5) | 40% (2/5) | 20% (1/5) | 0% (0/5) | 20% (1/5) |
| ER+/PR+ combined | 8% (1/12)b | 33% (4/12) | 33% (4/12)c | 33% (4/12) | 50% (6/12) |
| ER−/PR− in cancer cells of primary tumor (n = 18) | |||||
| Relapse within a 10-year period | 25% (2/8) | 63% (5/8) | 75% (6/8) | 63% (5/8) | 63% (5/8) |
| No relapse within a 10-year period | 60% (6/10) | 40% (4/10) | 80% (8/10) | 50% (5/10) | 20% (2/10) |
| ER−/PR− combined | 44% (8/18)b | 50% (9/18) | 78% (14/18)c | 56% (10/18) | 39% (7/18) |
| ER±/PR± combined (n = 30) | |||||
| Relapse within a 10-year period | 20% (3/15) | 47% (7/15) | 60% (9/15) | 60% (9/15) | 67% (10/15)d |
| No relapse within a 10-year period | 40% (6/15) | 40% (6/15) | 60% (9/15) | 33% (5/15) | 20% (3/15)d |
a
1/7 indicates one positive biopsy of a total of seven.
b–d
p value <0.05 between groups with identical letters (Fisher's exact test).